Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 5Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Melanoma 1Laryngeal Neoplasms 1Giant Cell Tumor of Bone 1Ganglioneuroblastoma 1Carcinoma 1Brain Neoplasms 1Alzheimer Disease 1

Interventions

Cisplatin 12pembrolizumab 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Paclitaxel 6Platinum 5Cyclophosphamide 51,2-diaminocyclohexaneplatinum II citrate 5fludarabine 4durvalumab 4cemiplimab 4Radiotherapy, Intensity-Modulated 4Radiotherapy 3Pemetrexed 3Oxaliplatin 3Nivolumab 3Fluorouracil 3Cetuximab 3Carboplatin 3Biopsy 3poly ICLC 2fludarabine phosphate 2cabozantinib 2atezolizumab 2Radiation 2Ipilimumab 2Interviews as Topic 2Heavy Ion Radiotherapy 2Gemcitabine 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma × Transurethral Resection of Bladder × Clear all
NCT06980038 2026-05-13

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡